Adherence to anticoagulation guidelines for atrial fibrillation: A district general hospital survey

British Journal of Cardiology

Volumn 11, Issue 6, 2004, Pages 474-477

  Mehta, Paresh A ^a   Grocott Mason, Richard ^b   Dubrey, Simon W ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b HILLINGDON HOSPITAL   (United Kingdom)

Author keywords

Anticoagulation; Atrial fibrillation; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE DURATION; DRUG METABOLISM; EMBOLISM; EMERGENCY WARD; FEMALE; GENERAL HOSPITAL; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; PROSPECTIVE STUDY; PUBLIC HOSPITAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SELF MONITORING; STROKE; UNITED KINGDOM;

EID: 10844253686     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Go AS, Hyleck EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5.
2. Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001;86:516-21.
3. Final consensus statement of the Royal College of Physicians of Edinburgh consensus conference on atrial fibrillation in hospitals and general practice. Br J Haematol 1999;104:195-6.
4. Kannel WB, Abbot RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation - the Framingham study. N Engl J Med 1982;306:1018-22.
5. Baine WB, Yu W, Weis KA. Trends and outcomes in the hospitalisation of older Americans for cardiac conduction disorders or arrhythmias, 1991-1998. J Am Geriatr Soc 2001;49:763-70.
6. Albers GW, Dalen JE, Laupacis A et al. Antithrombotic therapy in atrial fibrillation. Chest 2001;119:194S-206S.
7. Ezekowitz MD, James KE. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994;343:687-91.
8. Hobbs R. Identification and treatment of patients with atrial fibrillation in primary care. Heart 1999;81:333-4.
9. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-62.
10. Taylor FC, Cohen H, Ebrahim S. Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation. BMJ 2001;322:321-6.
11. Hart RG, Benevente O, McBride R, Pearce LA. Anti-thrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492-501.
12. Fuster V, Ryden LE, Asinger RW et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur Heart J 2001;22 1852-923.
13. McCrory DC, Matchar DB, Samsa G. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med 1995;155:277-81.
14. Gage BF, Boechler M, Doggette AL et al. Adverse outcomes and predictors of underuse of antithrombotic therapy in Medicare beneficiaries with chronic atrial fibrillation. Stroke 2000; 31 822-7.
15. Hylek EM, Go AS, Chang Y et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003;349:1019-26.
16. Mant JW, Richards SH, Hobbs FD et al. Protocol for Birmingham Atrial Fibrillation Treatment of the Aged study (BAFTA): a randomised controlled trial of warfarin versus aspirin for stroke prevention in the management of atrial fibrillation in an elderly primary care population. BMC Cardiovasc Disord 2003;3(1):9.
17. Cromheecke ME, Levi M, Colly LP et al. Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. Lancet 2000;356(9224):97-102.
18. Fitzmaurice DA, Murray ET, Gee KM et al. A randomised controlled trial of patient self management of oral anticoagulation treatment compared with primary care management. J Clin Pathol 2002;55:845-9.
19. Fitzmaurice DA, Murray ET, McCahon D et al. SMART Self-Management of Anticoagulation, a Randomised Trial. BMC Fam Pract 2003[Epub ahead of print].
20. Halperin JL. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 2003;146:431-8.
21. Wallentin L, Wilcox RG, Weaver WD et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 2003;362:789-97.
22. American Heart Association Scientific Sessions 2003, Orlando, Florida, US.